JP5145035B2 - β−クリプトキサンチンの使用 - Google Patents

β−クリプトキサンチンの使用 Download PDF

Info

Publication number
JP5145035B2
JP5145035B2 JP2007517026A JP2007517026A JP5145035B2 JP 5145035 B2 JP5145035 B2 JP 5145035B2 JP 2007517026 A JP2007517026 A JP 2007517026A JP 2007517026 A JP2007517026 A JP 2007517026A JP 5145035 B2 JP5145035 B2 JP 5145035B2
Authority
JP
Japan
Prior art keywords
cryptoxanthin
use according
vitamin
pharmaceutical composition
protein production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007517026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500376A5 (enExample
JP2008500376A (ja
Inventor
アン エイチンガー，
レジーナ ゴラルクズィク，
カリン ヴェルツ，
エイドリアン ヴィス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of JP2008500376A publication Critical patent/JP2008500376A/ja
Publication of JP2008500376A5 publication Critical patent/JP2008500376A5/ja
Application granted granted Critical
Publication of JP5145035B2 publication Critical patent/JP5145035B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
JP2007517026A 2004-05-18 2005-05-10 β−クリプトキサンチンの使用 Expired - Fee Related JP5145035B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04.011743.4 2004-05-18
EP04011743 2004-05-18
PCT/EP2005/005030 WO2005110122A1 (en) 2004-05-18 2005-05-10 USE OF β-CRYPTOXANTHIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012203513A Division JP2013047227A (ja) 2004-05-18 2012-09-14 β−クリプトキサンチンの使用

Publications (3)

Publication Number Publication Date
JP2008500376A JP2008500376A (ja) 2008-01-10
JP2008500376A5 JP2008500376A5 (enExample) 2011-11-17
JP5145035B2 true JP5145035B2 (ja) 2013-02-13

Family

ID=34966671

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007517026A Expired - Fee Related JP5145035B2 (ja) 2004-05-18 2005-05-10 β−クリプトキサンチンの使用
JP2012203513A Pending JP2013047227A (ja) 2004-05-18 2012-09-14 β−クリプトキサンチンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012203513A Pending JP2013047227A (ja) 2004-05-18 2012-09-14 β−クリプトキサンチンの使用

Country Status (9)

Country Link
US (1) US20080070980A1 (enExample)
EP (1) EP1748705B1 (enExample)
JP (2) JP5145035B2 (enExample)
KR (1) KR101317976B1 (enExample)
CN (1) CN1953669B (enExample)
AT (1) ATE484201T1 (enExample)
DE (1) DE602005024128D1 (enExample)
ES (1) ES2351701T3 (enExample)
WO (1) WO2005110122A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258111A1 (en) * 2006-07-28 2009-10-15 Katsuhiko Takayanagi Highly bioavailable oral administration composition of cryptoxanthin
US20090118227A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
JP5688697B2 (ja) * 2009-09-25 2015-03-25 国立大学法人愛媛大学 免疫蛋白質の産生促進剤
JP5909084B2 (ja) * 2010-12-15 2016-04-26 アークレイ株式会社 安定化βクリプトキサンチン含有水およびその用途
CN102219721B (zh) * 2011-04-02 2013-08-07 秦皇岛大惠生物技术有限公司 一种含有β-隐黄质的浓缩物的提取方法与采用该方法所得到的浓缩物及其用途
CA2841411C (en) * 2011-07-13 2017-09-12 University Of Georgia Research Foundation, Inc. Use of xanthophyll carotenoids to improve visual performance and neural efficiency
MX367861B (es) * 2012-10-04 2019-09-09 Abbott Lab Una composición nutricional para usarse en la preservación del músculo esquelético.
JP5687682B2 (ja) * 2012-12-20 2015-03-18 ユニチカ株式会社 カルシウム吸収促進組成物
CN105073711A (zh) 2013-01-24 2015-11-18 欧米尼艾克蒂夫健康技术有限公司 植物来源的β-隐黄素和其制备方法
US20160106776A1 (en) * 2013-05-31 2016-04-21 Dsm Ip Assets B.V. Feed supplement and its use
MX394164B (es) * 2015-01-15 2025-03-24 Dsm Ip Assets Bv COMBINACION DE 25-HIDROXIVITAMINA D Y ANTIINFLAMATORIO PARA NIVELES SOSTENIDOS DE 17-ß ESTRADIOL EN PLASMA.
US10568846B2 (en) 2015-04-27 2020-02-25 Omniactive Health Technologies Limited Betacryptoxanthin compositions, processes for preparation and uses thereof
CN104906112B (zh) * 2015-05-20 2018-02-23 杨克西 一种促进蛋白质合成的组合物及其制备方法和用途
JP2019218316A (ja) * 2018-06-21 2019-12-26 公立大学法人大阪 オートファジー活性向上剤
SG10201900604TA (en) 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Pre-natal beta-cryptoxanthin benefits children
WO2022018161A1 (en) 2020-07-22 2022-01-27 Dsm Ip Assets B.V. Beta-cryptoxanthin crystal forms, liquid formulations thereof and processes for their manufacture
WO2022018162A1 (en) 2020-07-22 2022-01-27 Dsm Ip Assets B.V. FORMULATIONS OF NEW β-CRYPTOXANTHIN CRYSTAL FORM, PROCESSES FOR THEIR MANUFACTURE AND THEIR USES
CN115530381A (zh) * 2022-08-17 2022-12-30 中南大学 预防产前抑郁症的蛋白粉及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
US8148431B2 (en) * 2002-10-25 2012-04-03 Kemin Health, L.C. Osteogenesis promoter containing β-cryptoxanthin as the active ingredient

Also Published As

Publication number Publication date
DE602005024128D1 (de) 2010-11-25
KR20070011515A (ko) 2007-01-24
KR101317976B1 (ko) 2013-10-14
US20080070980A1 (en) 2008-03-20
EP1748705A1 (en) 2007-02-07
JP2013047227A (ja) 2013-03-07
JP2008500376A (ja) 2008-01-10
ATE484201T1 (de) 2010-10-15
EP1748705B1 (en) 2010-10-13
CN1953669A (zh) 2007-04-25
CN1953669B (zh) 2010-06-16
ES2351701T3 (es) 2011-02-09
WO2005110122A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
JP2013047227A (ja) β−クリプトキサンチンの使用
TWI402069B (zh) 含斛黃素組合物
US9492424B2 (en) Muscle atrophy inhibitor
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
KR20080108523A (ko) 지방 축적 억제제
JP2017506651A (ja) 脂肪肝の低減または予防のための組成物および方法
US20220387464A1 (en) Inositol phosphate-containing composition
US9801404B2 (en) IGF-1 production-promoting agent
JP6716330B2 (ja) ウロプラキン発現促進剤
JP5922862B2 (ja) ミトコンドリア機能向上剤
JPWO2006095675A1 (ja) 抗動脈硬化組成物
JP2021078397A (ja) 脂質減少促進剤
JP2024100951A (ja) アトロジン－１発現抑制剤
JPWO2008136173A1 (ja) スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
JP6117963B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
JP5909173B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
JP2008007446A (ja) 神経栄養因子とその利用法
JP2024109823A (ja) アトロジン－１発現抑制剤
JP2022129479A (ja) 肝機能向上剤および肝機能向上用経口組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121113

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121126

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151130

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5145035

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees